Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Withdrawal: BRCA1-induced apoptosis involves inactivation of ERK1/2 activities.

Yan Y, Haas JP, Kim M, Sgagias MK, Cowan KH.

J Biol Chem. 2019 May 17;294(20):8309. doi: 10.1074/jbc.W119.009053. No abstract available.

2.

Correction: KSR1 is required for cell cycle reinitiation following DNA damage.

Razidlo GL, Johnson HJ, Stoeger SM, Cowan KH, Bessho T, Lewis RE.

J Biol Chem. 2018 Dec 7;293(49):19136. doi: 10.1074/jbc.AAC118.006696. No abstract available.

3.

Breast Cancer Collaborative Registry informs understanding of factors predicting sleep quality.

Berger AM, Kupzyk KA, Djalilova DM, Cowan KH.

Support Care Cancer. 2019 Apr;27(4):1365-1373. doi: 10.1007/s00520-018-4417-5. Epub 2018 Aug 15.

PMID:
30112722
4.

Breast Cancer Risk Reduction, Version 2.2015.

Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R.

J Natl Compr Canc Netw. 2015 Jul;13(7):880-915.

PMID:
26150582
5.

Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.

Downs B, Kim YC, Xiao F, Snyder C, Chen P, Fleissner EA, Becirovic D, Wen H, Sherman S, Cowan KH, Lynch HT, Wang SM.

Breast Cancer Res Treat. 2015 May;151(1):219-24. doi: 10.1007/s10549-015-3358-7. Epub 2015 Apr 2.

PMID:
25833210
6.

Exome analysis reveals differentially mutated gene signatures of stage, grade and subtype in breast cancers.

Li Y, Wang X, Vural S, Mishra NK, Cowan KH, Guda C.

PLoS One. 2015 Mar 24;10(3):e0119383. doi: 10.1371/journal.pone.0119383. eCollection 2015.

7.

Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation.

Yan Y, Hein AL, Etekpo A, Burchett KM, Lin C, Enke CA, Batra SK, Cowan KH, Ouellette MM.

Oncotarget. 2014 Nov 15;5(21):10251-70.

8.

Family-specific, novel, deleterious germline variants provide a rich resource to identify genetic predispositions for BRCAx familial breast cancer.

Wen H, Kim YC, Snyder C, Xiao F, Fleissner EA, Becirovic D, Luo J, Downs B, Sherman S, Cowan KH, Lynch HT, Wang SM.

BMC Cancer. 2014 Jun 26;14:470. doi: 10.1186/1471-2407-14-470.

9.

A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation.

Yan Y, Hein AL, Greer PM, Wang Z, Kolb RH, Batra SK, Cowan KH.

Oncogene. 2015 Apr 23;34(17):2215-26. doi: 10.1038/onc.2014.167. Epub 2014 Jun 9.

10.

Genome instability in blood cells of a BRCA1+ breast cancer family.

Xiao F, Kim YC, Snyder C, Wen H, Chen PX, Luo J, Becirovic D, Downs B, Cowan KH, Lynch H, Wang SM.

BMC Cancer. 2014 May 19;14:342. doi: 10.1186/1471-2407-14-342.

11.

Can unknown predisposition in familial breast cancer be family-specific?

Lynch H, Wen H, Kim YC, Snyder C, Kinarsky Y, Chen PX, Xiao F, Goldgar D, Cowan KH, Wang SM.

Breast J. 2013 Sep-Oct;19(5):520-8. doi: 10.1111/tbj.12145. Epub 2013 Jun 26.

PMID:
23800003
12.

ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation.

Kolb RH, Greer PM, Cao PT, Cowan KH, Yan Y.

PLoS One. 2012;7(11):e50281. doi: 10.1371/journal.pone.0050281. Epub 2012 Nov 16.

13.

RAC1 GTPase plays an important role in γ-irradiation induced G2/M checkpoint activation.

Yan Y, Greer PM, Cao PT, Kolb RH, Cowan KH.

Breast Cancer Res. 2012 Apr 11;14(2):R60.

14.

Breast cancer risk reduction.

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH.

J Natl Compr Canc Netw. 2010 Oct;8(10):1112-46. No abstract available.

PMID:
20971838
15.

Protein phosphatase 2A has an essential role in the activation of gamma-irradiation-induced G2/M checkpoint response.

Yan Y, Cao PT, Greer PM, Nagengast ES, Kolb RH, Mumby MC, Cowan KH.

Oncogene. 2010 Jul 29;29(30):4317-29. doi: 10.1038/onc.2010.187. Epub 2010 May 24.

16.

KSR1 is required for cell cycle reinitiation following DNA damage.

Razidlo GL, Johnson HJ, Stoeger SM, Cowan KH, Bessho T, Lewis RE.

J Biol Chem. 2009 Mar 13;284(11):6705-15. doi: 10.1074/jbc.M806457200. Epub 2009 Jan 15. Erratum in: J Biol Chem. 2018 Dec 7;293(49):19136.

17.

Tumor and iatrogenic regulation of myeloid precursors and their potential to limit immune therapy.

Talmadge JE, Cowan KH, Reed EC.

Immunotherapy. 2009 Jan;1(1):5-9. doi: 10.2217/1750743X.1.1.5. Review. No abstract available.

18.

Characterization of kinase suppressor of Ras-1 expression and anticancer drug sensitivity in human cancer cell lines.

Stoeger SM, Cowan KH.

Cancer Chemother Pharmacol. 2009 Apr;63(5):807-18. doi: 10.1007/s00280-008-0794-7. Epub 2008 Jul 26.

PMID:
18661133
19.

Gamma-irradiation-induced DNA damage checkpoint activation involves feedback regulation between extracellular signal-regulated kinase 1/2 and BRCA1.

Yan Y, Black CP, Cao PT, Haferbier JL, Kolb RH, Spieker RS, Ristow AM, Cowan KH.

Cancer Res. 2008 Jul 1;68(13):5113-21. doi: 10.1158/0008-5472.CAN-07-5818.

20.

Breast cancer risk reduction.

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2007 Sep;5(8):676-701. No abstract available.

PMID:
17927926
21.

Irradiation-induced G2/M checkpoint response requires ERK1/2 activation.

Yan Y, Black CP, Cowan KH.

Oncogene. 2007 Jul 12;26(32):4689-98. Epub 2007 Feb 5.

PMID:
17297454
22.

Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells.

Yaar M, Eller MS, Panova I, Kubera J, Wee LH, Cowan KH, Gilchrest BA.

Breast Cancer Res. 2007;9(1):R13.

23.

Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.

Muraoka-Cook RS, Caskey LS, Sandahl MA, Hunter DM, Husted C, Strunk KE, Sartor CI, Rearick WA Jr, McCall W, Sgagias MK, Cowan KH, Earp HS 3rd.

Mol Cell Biol. 2006 Sep;26(17):6412-24.

24.

Neural stem cells in the adult ciliary epithelium express GFAP and are regulated by Wnt signaling.

Das AV, Zhao X, James J, Kim M, Cowan KH, Ahmad I.

Biochem Biophys Res Commun. 2006 Jan 13;339(2):708-16. Epub 2005 Nov 21.

PMID:
16332461
25.

BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53.

Basma H, El-Refaey H, Sgagias MK, Cowan KH, Luo X, Cheng PW.

J Biomed Sci. 2005 Dec;12(6):999-1011. Epub 2005 Oct 14.

PMID:
16228292
26.

Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity.

Kim M, Yan Y, Kortum RL, Stoeger SM, Sgagias MK, Lee K, Lewis RE, Cowan KH.

Cancer Res. 2005 May 15;65(10):3986-92.

27.

BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.

Yan Y, Spieker RS, Kim M, Stoeger SM, Cowan KH.

Oncogene. 2005 May 5;24(20):3285-96.

PMID:
15735702
28.

Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS.

Sgagias MK, Wagner KU, Hamik B, Stoeger S, Spieker R, Huber LJ, Chodosh LA, Cowan KH.

Cell Cycle. 2004 Nov;3(11):1451-6. Epub 2004 Nov 8.

PMID:
15492509
29.

Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancer.

Saif MW, Leitman SF, Cusack G, Horne M, Freifeld A, Venzon D, PremKumar A, Cowan KH, Gress RE, Zujewski J, Kasten-Sportes C.

Ann Oncol. 2004 Sep;15(9):1366-72.

PMID:
15319243
30.
31.

The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and Genistein is effective in inhibiting pancreatic cancer growth.

Nozawa F, Itami A, Saruc M, Kim M, Standop J, Picha KS, Cowan KH, Pour PM.

Pancreas. 2004 Jul;29(1):45-52.

PMID:
15211111
32.

Adenovirus expressing p27KIP1 induces apoptosis against cholangiocarcinoma cells by triggering Fas ligand on the cell surface.

Yamamoto K, Katayose Y, Suzuki M, Unno M, Sasaki T, Mizuma M, Shiraso S, Ohtuka H, Cowan KH, Seth P, Matsuno S.

Hepatogastroenterology. 2003 Nov-Dec;50(54):1847-53.

PMID:
14696417
33.

A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.

Zujewski JA, Eng-Wong J, O'Shaughnessy J, Venzon D, Chow C, Danforth D, Kohler DR, Cusack G, Riseberg D, Cowan KH.

Breast Cancer Res Treat. 2003 Sep;81(1):41-51.

PMID:
14531496
34.

Recombinant adenovirus-mediated p14(ARF) overexpression sensitizes human breast cancer cells to cisplatin.

Deng X, Kim M, Vandier D, Jung YJ, Rikiyama T, Sgagias MK, Goldsmith M, Cowan KH.

Biochem Biophys Res Commun. 2002 Aug 30;296(4):792-8.

PMID:
12200117
35.

BRCA1-induced apoptosis involves inactivation of ERK1/2 activities.

Yan Y, Haas JP, Kim M, Sgagias MK, Cowan KH.

J Biol Chem. 2002 Sep 6;277(36):33422-30. Epub 2002 Jun 24. Retraction in: J Biol Chem. 2019 May 17;294(20):8309.

36.

BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage.

Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC.

Nat Genet. 2002 Mar;30(3):285-9. Epub 2002 Feb 11.

PMID:
11836499
37.

Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations.

Lawrence JA, Adamson PC, Caruso R, Chow C, Kleiner D, Murphy RF, Venzon DJ, Shovlin M, Noone M, Merino M, Cowan KH, Kaiser M, O'Shaughnessy J, Zujewski J.

J Clin Oncol. 2001 May 15;19(10):2754-63.

PMID:
11352969
38.

Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter.

Vandier D, Rixe O, Besnard F, Kim M, Rikiyama T, Goldsmith M, Brenner M, Gouyette A, Cowan KH.

Cancer Gene Ther. 2000 Aug;7(8):1120-6.

39.

Induction of apoptosis in p16INK4A mutant cell lines by adenovirus-mediated overexpression of p16INK4A protein.

Kim M, Katayose Y, Rojanala L, Shah S, Sgagias M, Jang L, Jung YJ, Lee SH, Hwang SG, Cowan KH.

Cell Death Differ. 2000 Aug;7(8):706-11.

40.

Multidrug resistance.

Schneider E, Paul D, Ivy P, Cowan KH.

Cancer Chemother Biol Response Modif. 1999;18:152-77. Review. No abstract available.

PMID:
10800482
41.

Detection of circulating tumor cells and micrometastases in stage II, III, and IV breast cancer patients utilizing cytology and immunocytochemistry.

Fetsch PA, Cowan KH, Weng DE, Freifield A, Filie AC, Abati A.

Diagn Cytopathol. 2000 May;22(5):323-8.

PMID:
10790242
42.

Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12).

Paul D, Qazilbash MH, Song K, Xu H, Sinha BK, Liu J, Cowan KH.

Cancer Gene Ther. 2000 Feb;7(2):308-15.

43.

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH.

J Clin Oncol. 2000 Feb;18(4):927-41.

PMID:
10673536
44.

BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression.

MacLachlan TK, Somasundaram K, Sgagias M, Shifman Y, Muschel RJ, Cowan KH, El-Deiry WS.

J Biol Chem. 2000 Jan 28;275(4):2777-85.

45.

Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.

Conley B, O'Shaughnessy J, Prindiville S, Lawrence J, Chow C, Jones E, Merino MJ, Kaiser-Kupfer MI, Caruso RC, Podgor M, Goldspiel B, Venzon D, Danforth D, Wu S, Noone M, Goldstein J, Cowan KH, Zujewski J.

J Clin Oncol. 2000 Jan;18(2):275-83.

PMID:
10637240
46.

Tamoxifen and fenretinide in women with metastatic breast cancer.

Zujewski J, Pai L, Wakefield L, Giusti R, Dorr FA, Flanders C, Caruso R, Kaiser M, Goodman L, Merino M, Gossard M, Noone MA, Denicoff A, Venzon D, Cowan KH, O'Shaughnessy JA.

Breast Cancer Res Treat. 1999 Oct;57(3):277-83.

PMID:
10617304
47.

BRCA1 signals ARF-dependent stabilization and coactivation of p53.

Somasundaram K, MacLachlan TK, Burns TF, Sgagias M, Cowan KH, Weber BL, el-Deiry WS.

Oncogene. 1999 Nov 11;18(47):6605-14.

48.
49.

Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.

Cowan KH, Moscow JA, Huang H, Zujewski JA, O'Shaughnessy J, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinberg S, Wilson W, Goldspiel B, Read EJ, Leitman SF, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis A.

Clin Cancer Res. 1999 Jul;5(7):1619-28.

50.

A novel adenoviral vector expressing human Fas/CD95/APO-1 enhances p53-mediated apoptosis.

Rakkar AN, Katayose Y, Kim M, Craig C, Ohri E, Li Z, Cowan KH, Seth P.

Cell Death Differ. 1999 Apr;6(4):326-33.

Supplemental Content

Loading ...
Support Center